Catalog ID ORXNA Orexin-A/Hypocretin-1, Spinal Fluid
Useful For
Aiding in the diagnosis and differentiation of type 1 narcolepsy from other causes of hypersomnolence
This assay is not intended for use as a screening test.
Ordering Guidance
Orexin-A (hypocretin-1) deficiency is the hallmark of narcolepsy type 1. The diagnostic criteria for type 1 narcolepsy include the presence of cataplexy and/or measured cerebrospinal fluid orexin-A/hypocretin-1 concentrations less than or equal to 110 pg/mL. Alternative testing for narcolepsy type 1 includes mean latency of 8 minutes in the clinical multiple sleep latency test, with evidence of sleep-onset rapid eye movement periods and cataplexy.
Specimen Required
Patient Preparation: Patient should not have recently received radioisotopes, either therapeutically or diagnostically, due to potential assay interference.
Collection Container/Tube: Sterile vial
Submission Container/Tube: Plain vial with no additives
Specimen Volume: 1.5 mL
Pediatric Volume: 0.5 mL minimum volume
Collection Instructions:
1. Obtain aliquot from second collection vial (preferred, not required).
2. Hemolyzed specimens will give false-positive results. Specimens should be centrifuged to remove any red cells prior to shipping.
Reference Values
Normal individuals should be >200 pg/mL
Previous literature has defined cerebrospinal fluid orexin-A/hypocretin-1 concentrations of 110 pg/mL or below as being consistent with narcolepsy type 1-(Mignot E: Arch Neurol 2002:59;1553-1562). Concentrations between 111 to 200 pg/mL are considered intermediate and have limited diagnostic utility for narcolepsy, as they may be representative of other neurological disorders. Concentrations above 200 pg/mL are considered normal.
Method Name
Radioimmunoassay (RIA)
Reporting Name
Orexin-A/Hypocretin-1, CSFSpecimen Type
CSFSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Frozen | 120 days |
Reject Due To
Gross hemolysis | Reject |
Day(s) Performed
Twice monthly (Second and fourth Monday)
Performing Laboratory
Mayo Clinic Laboratories in RochesterSecondary ID
604230Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83519
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ORXNA | Orexin-A/Hypocretin-1, CSF | 91670-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
604230 | Orexin-A/Hypocretin-1, CSF | 91670-0 |
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.